Furthermore, in vivo studies demonstrated the higher ability of angiopep-2-modified GOLPH3-siRNA-liposomes to accumulate in the brain and effectively inhibit glioma growth in comparison with free GOLPH3-siRNA, suggesting the potential of this liposomal formulation for glioblastoma treatment [104]. This evidence concerns the gene GOLPH3 and glioma.